Protocol Ledger

NCT07498478 · Phase II · RECRUITING

Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

Interventional Phase II clinical trial protocol NCT07498478 sponsored by TransThera Sciences (Nanjing) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-17 Enrollment: 94 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07498478
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)94 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07498478
Protocol FieldVerified Registry Value
NCT IdentifierNCT07498478
Consolidated Lead SponsorTransThera Sciences (Nanjing)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment94 participants (ESTIMATED)
Registered Start Date2026-03-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07498478
Hospital Research SiteLocationSite Profile
Guangdong Provincial People's HospitalGuangzhou, ChinaOpen Hospital Dossier ->
Zhongnan Hospital of Wuhan UniversityWuhan, ChinaOpen Hospital Dossier ->
Hunan Cancer HospitalChangsha, ChinaOpen Hospital Dossier ->
Jiangsu Province HospitalNanjing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI